Fecal microbiota transplant, its usefulness beyond Clostridioides difficile in gastrointestinal diseases

Gastroenterol Hepatol. 2022 Mar;45(3):223-230. doi: 10.1016/j.gastrohep.2021.05.009. Epub 2021 Jun 9.
[Article in English, Spanish]

Abstract

Fecal microbiota transplant (FMT) is currently recommended for recurrent Clostridioidesdifficile infection. However, it is interesting to acknowledge the potential therapeutic role in other diseases associated with dysbiosis. This review will focus on the current and potential indications of FMT in gastrointestinal diseases, evaluating the available evidence and also exposing the necessary requirements to carry it out.

Keywords: Clostridioides difficile; Enfermedades gastrointestinales; Fecal microbiota transplantation; Gastrointestinal illness; Microbioma; Microbiome; Trasplante microbiota fecal.

Publication types

  • Review

MeSH terms

  • Cholangitis, Sclerosing / therapy
  • Clostridioides difficile
  • Dysbiosis / therapy
  • Enterocolitis, Pseudomembranous / therapy
  • Fecal Microbiota Transplantation*
  • Gastrointestinal Diseases / therapy*
  • Gastrointestinal Microbiome
  • Hepatic Encephalopathy / therapy
  • Hepatitis, Alcoholic / therapy
  • Humans
  • Inflammatory Bowel Diseases / therapy
  • Irritable Bowel Syndrome / therapy
  • Non-alcoholic Fatty Liver Disease / therapy
  • Recurrence